LDS/Medical Tests/OVA 1, Overa (OVA1 Next Generation) Testing

OVA 1, Overa (OVA1 Next Generation) Testing

The OVA1™ test is a qualitative serum test that is used to help determine whether ovarian tumors are malignant or not. This test is used when the physician’s independent clinical and radiological evaluation does not indicate malignancy, but is still suspected. The results from this test are a calculation from five different analytes: Transthyretin (prealbumin), Apolipoprotein A-1, β2 Microglobulin, Transferrin, and Cancer Antigen 125. The scores from this panel are combined using software to generate a number from 0.0 to 10.0. This number correlates with the likelihood the patient has malignant ovaryian cancer. This is not a screening mechanism and should not be used as a standalone test.

Factors that are required for the test are: patients should be over 18 years of age, have an ovarian mass, surgery is planned, and has not yet been referred to an oncologist. This test should not be used in patients who have had a malignancy in the last five years or a rheumatoid factor concentration that is ≥250 IU/mL. Another requirement is an assessment of menopausal state to interpret the correct reference ranges. This is accomplished by either patient history or by including a LH and FSH in the blood work.

  • To evaluate an ovarian mass for cancer prior to a planned surgery
  • Assist in detecting ovarian malignancies
  • Rule out ovarian cancer

Increased in:

  • Ovarian Cancer
  • Cervical Cancer
  • Colon Cancer
  • Endometrial Cancer
  • Leukemia
  • Lymphoma
  • Autoimmune Disease
  • Cardiac Disease
  • Endometriosis
  • Kidney Disease
  • Pregnancy
Menopausal Status Interpretation OVA1 Score
Pre-menopausal Low probability of malignancy OVA1 < 5.0
High probability of malignancy OVA1 ≥ 5.0
Post-menopausal Low probability of malignancy OVA1 < 4.4
High probability of malignancy OVA1 ≥ 4.4
Refer to each listed analyte in the test overview for methodology.

Serum (SST). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
FSH, LH, Complete Blood Count, Comprehensive Metabolic Panel, Antinuclear Antibody.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Gynecol Oncol. 2013 Feb;128(2):252-9. [PMID: 231782770]
  • OVA1™ Test Product Insert, Version 2.0: 27Jan10, Distributed by Vermillion, Inc., 47350 Fremont Blvd. Fremont, CA 94538, www.vermillion.com.
  • OVA1™ Test Bulletin, TB2602-HS:02/2010, Distributed by Quest Diagnostic and the Nichols Institute, 14225 Newbrook Drive, PO Box 10841, Chantilly, CA 20153, www.nicholsinstitute.com
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login